Our findings indicate that anti-PD1 therapy uniquely induces the expression of inhibitory receptors on TILs when used against neuroblastoma tumors with induced MMR deficiency, but this is not the case with anti-CTLA4 therapy. Here, PDCD1 is linked to mismatch repair cancer syndrome 1.